Formulary guidance and transparency from P&T to point of care


Reality Check on PCSK9

Market access for PCSK9s reveals differences in payer coverage across each major channel, as well as specific trends in the drug landscape.  

To help make sense of this new research, MMIT's team of experts has analyzed the data for you and summarized the key findings:

  • Payer Insights: How pharmacy and medical benefit coverage is shifting 
  • Class Trends: Understand the implications of how manufacturer patient support programs impact utilization
  • Key Findings: The incredibly advantaged access of generic treatments creates a complex PCSK9 landscape

What can pharma do to curb this trend and overcome these challenges?

Get the data behind this change and how it could impact your market access plans from MMIT's team.  Their clinical and policy backgrounds provide a unique and expert perspective to help expand your knowledge in the class and guide your decision-making process.

Download the full Reality Check now.